Please select an option below to help us tailor your newsletter to best suit your content interests!
A Phase 3, Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician's Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Immunotherapy (MK-2870-005/ENGOT-en23/GOG-3095)
VIEW TRIAL ON CLINICALTRIALS.GOVEndometrial Cancer
Stage 3
Phase 3
Open to Enrollment
Post-immunotherapy
Sacituzumab tirumotecan
TROP-2 ADC
Todd Tillmanns, MD
Merck Sharp and Dohme
Carcinoma or carcinosarcoma
Inclusion Criteria:
Exclusion Criteria:
Endometrial, uterine
Stage 3
Phase 3
Open to Enrollment
1st Line
Trastuzumab or trastuzumab/pertuzumab
HER2 antibody
Todd Tillmanns, MD
NRG Oncology
Serous carcinoma or carcinosarcoma